Janssen Pharmaceuticals

J&J settles antipsychotics cases in historic $2.2B deal

J&J settles antipsychotics cases in historic $2.2B deal

By

Pharmaceuticals giant Johnson & Johnson and some subsidiaries will pay more than $2.2 billion to settle claims that they inappropriately promoted antipsychotic drugs for use in nursing homes. The agreement also will settle kickback charges related to the nation's largest long-term care pharmacy, Omnicare.

Following Hurricane Sandy, drug makers get back to business

The typical long-term care resident requires eight or more medications daily. So with Hurricane Sandy ripping through the pharmaceutical corridor last week, many operators were rightfully concerned about possible medication shortages. The good news is that most drug firms appear to be getting back on their feet quickly

J&J to pay $181 million for Risperdal settlement

J&J to pay $181 million for Risperdal settlement

By

Janssen Pharmaceuticals, a unit of Johnson & Johnson, will pay $181 million to settle charges that it marketed antipsychotic medications for medically unapproved purposes.

J & J pays $158 million to settle Texas Medicaid fraud lawsuit

J & J pays $158 million to settle Texas Medicaid fraud lawsuit

Johnson & Johnson has agreed to pay $158 million to settle a Medicaid fraud lawsuit. The lawsuit accused J & J subsidiary Janssen Pharmaceuticals of giving state officials kickbacks in exchange for putting the antipsychotic Risperdal on an approved list for Medicaid recipients.